Zacks: Brokerages Set $8.50 Price Target for Neurotrope Inc (NASDAQ:NTRP)
Neurotrope Inc (NASDAQ:NTRP) has received a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Neurotrope’s rating score has declined by 100% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a 12-month consensus target price of $8.50 for the company and are anticipating that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Neurotrope an industry rank of 76 out of 256 based on the ratings given to related companies.
Several equities research analysts have recently weighed in on the company. Maxim Group cut Neurotrope from a “buy” rating to a “hold” rating in a research report on Monday. Zacks Investment Research upgraded Neurotrope from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research note on Wednesday, August 21st. Janney Montgomery Scott lowered Neurotrope from a “buy” rating to a “neutral” rating and cut their target price for the company from $13.00 to $1.00 in a research note on Wednesday. Finally, ValuEngine upgraded Neurotrope from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
Shares of NTRP traded down $0.07 during mid-day trading on Monday, hitting $0.83. The company’s stock had a trading volume of 5,242 shares, compared to its average volume of 132,961. Neurotrope has a one year low of $0.81 and a one year high of $9.38. The firm has a market capitalization of $13.02 million, a PE ratio of -0.62 and a beta of 2.41. The stock’s 50-day moving average is $5.08 and its two-hundred day moving average is $5.91.
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Read More: How to calculate compound interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.